IGC Pharma, Inc.
IGCIGC Pharma, Inc. in brief
IGC Pharma, Inc. is a listed company in the Biotechnology industry, based in Potomac, Maryland, USA. Its market value was $29 M on 26 October 2026, which makes it the 23,113th largest listed company in the world and the 4,033rd largest in the USA on this site. In the year to March 2025 it had sales of $1 M and a net loss of $7 M. Its largest product and service lines by sales in 2025 were Plant and Cannabinoid (100%), Tolling/White labeling service (91%) and Infrastructure (13%). By market, the largest shares of its 2025 sales came from USA (100%). Its shares trade under the symbol IGC (NYSE).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About IGC Pharma, Inc.
IGC is a Maryland corporation established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. Please refer to Note 1, “Nature of Operations” and Item 8 of this Annual Report on Form 10-K, for further information on business segments.
Our mission is to improve the lives of individuals affected by Alzheimer’s disease by addressing both its symptoms and the disease. Our near-term focus is on advancing IGC-AD1, our lead drug candidate currently in Phase 2 clinical trials targeting agitation in Alzheimer’s patients. We are also investing in our early-stage pipeline of investigational therapies and exploring Artificial Intelligence (AI) powered models designed to identify early markers of Alzheimer’s. We believe that combining scientific innovation with operational execution, including leveraging our internal contract research organization, positions us to efficiently advance our pipeline toward commercialization, although there can be no assurance thereof. Our long-term strategy is to build a portfolio of differentiated therapies that not only address symptomatic needs but also target disease-modifying mechanisms, thereby creating sustainable value for patients, caregivers, and shareholders.
From the company's annual report filed with the US SEC: read the report
IGC Pharma, Inc. timeline
- 2005
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2006
- 🔔Initial public offering as India Globalization Capital, Inc.Final prospectus filed with the SEC on 7 March 2006; shares registered for exchange trading on 8 March 2006.
- 2023
- ✎Renamed IGC Pharma, Inc.Formerly India Globalization Capital, Inc..
Events of IGC Pharma, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 24.9×
- Price / book
- 3.9×
- Free cash flow yield
- -16.8%
- Net margin (TTM)
- -787.2%
- Operating margin
- -586.6%
- Return on equity
- -124.1%
- Liabilities / assets
- 23.6%
- Net debt
- $-1M
- Revenue growth
- -5.2%
- R&D / revenue
- 288.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2025 | $1M | -5.2% | $-7M | $-7M | -560.6% |
| Mar 2024 | $1M | +47.3% | $-10M | $-13M | -970.1% |
| Mar 2023 | $1M | +127.5% | $-12M | $-12M | -1264.8% |
| Mar 2022 | $0M | -55.6% | $-15M | $-15M | -3755.0% |
| Mar 2021 | $1M | -77.9% | $-9M | $-9M | -978.9% |
| Mar 2020 | $4M | -20.5% | $-7M | $-7M | -179.9% |
| Mar 2019 | $5M | +133.8% | $-5M | $-4M | -80.1% |
| Mar 2018 | $2M | — | $-2M | $-2M | -81.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2025 | $-5M | $0M | $-5M | $-0.09 | — |
| Mar 2024 | $-5M | $0M | $-5M | $-0.22 | — |
| Mar 2023 | $-7M | $0M | $-7M | — | — |
| Mar 2022 | $-7M | $0M | $-8M | — | — |
| Mar 2021 | $-11M | $1M | $-12M | $-0.21 | — |
| Mar 2020 | $-9M | $4M | $-13M | $-0.19 | — |
| Mar 2019 | $-3M | $0M | $-3M | $-0.13 | — |
| Mar 2018 | $-2M | $0M | $-2M | $-0.06 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+73.7% on a year earlier), net income $-2M. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Oct 22, 2026DEF 14AProxy statement
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 14, 20268-KCurrent reportRegulation FD disclosure
- Jul 6, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Jun 8, 20268-KCurrent reportMaterial agreement · New financial obligation
- May 15, 202610-QQuarterly report · period to Mar 2026
- Apr 20, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Mar 30, 20268-KCurrent reportOther events
- Mar 18, 202610-KTTransition report · period to Dec 2025
- Mar 12, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Jan 6, 20268-KCurrent reportMaterial agreement
Official filings of IGC Pharma, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-7 M
- Net income
- $-7 M
For year ending March-2025 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $2 M
- Total equity
- $7 M
As of December-2025
Top 29 institutional investors in IGC Pharma, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 1,041,137 | +161,743 (+18.39%) | 0.89% | $0 M | Nov 6, 2026 |
| 2 | AdvisorShares Investments LLC | 939,481 | +261,001 (+38.47%) | 0.81% | $0 M | Nov 9, 2026 |
| 3 | Vanguard Capital Management LLC | 870,714 | +55,800 (+6.85%) | 0.75% | $0 M | Nov 13, 2026 |
| 4 | Citadel Advisors LLC | 735,693 | +298,376 (+68.23%) | 0.63% | $0 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 703,798 | 0 (0.00%) | 0.60% | $0 M | Nov 13, 2026 |
| 6 | Renaissance Technologies LLC | 653,458 | +366,850 (+128.00%) | 0.56% | $0 M | Nov 12, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 419,413 | 0 (0.00%) | 0.36% | $0 M | Nov 13, 2026 |
| 8 | State Street Corp | 274,899 | +74,100 (+36.90%) | 0.24% | $0 M | Nov 12, 2026 |
| 9 | Northern Trust Corp | 170,274 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 10 | UBS Group AG | 98,716 | +98,715 (+9871500.00%) | 0.08% | $0 M | Nov 10, 2026 |
| 11 | Lawood & Co | 75,000 | 0 (0.00%) | 0.06% | $0 M | Oct 9, 2026 |
| 12 | Goldman Sachs Group Inc | 65,541 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 13 | Dearborn Partners LLC | 59,401 | -59,401 (-50.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 14 | Fisher Asset Management, LLC | 43,400 | 0 (0.00%) | 0.04% | $0 M | Nov 6, 2026 |
| 15 | Truist Financial Corp | 36,667 | -12,000 (-24.66%) | 0.03% | $0 M | Oct 30, 2026 |
| 16 | Morgan Stanley | 35,118 | -80 (-0.23%) | 0.03% | $0 M | Nov 13, 2026 |
| 17 | Schneider Downs Wealth Management Advisors, LP | 30,000 | New | 0.03% | $0 M | Oct 27, 2026 |
| 18 | Tower Research Capital LLC (TRC) | 16,624 | -10,983 (-39.78%) | 0.01% | $0 M | Nov 16, 2026 |
| 19 | Vanguard Global Advisers, LLC | 14,944 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 20 | Wealthcare Advisory Partners LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 21, 2026 |
| 21 | Burnham & Co LLC | 6,000 | +1,000 (+20.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 22 | Geneos Wealth Management Inc. | 3,000 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 23 | Group One Trading LLC | 1,806 | -794 (-30.54%) | 0.00% | $0 M | Nov 10, 2026 |
| 24 | SimplyRIA Advisor Network | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 25 | Farther Finance Advisors, LLC | 110 | +9 (+8.91%) | 0.00% | $0 M | Oct 8, 2026 |
All 29 institutional investors: 26 to 29, with who bought and sold →
Mutual funds holding IGC Pharma, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 814,914 | $0 M | 0.70% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 630,022 | $0 M | 0.54% | <0.01% | +38% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 98,554 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 95,369 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
As of Jun 30, 2026
Insider trading at IGC Pharma, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ram MukundaCEO, Director | Gift | -100,000 | — | — | 6.78 M | Form 4 |
| filed | Claudia GrimaldiPFO, Director | Gift | -150,000 | — | — | 3.27 M | Form 4 |
| filed | Ram MukundaCEO, Director | Gift | -100,000 | — | — | 6.68 M | Form 4 |
| filed | Claudia GrimaldiPFO, Director | Grant or award | +2.05 M | $0.270 | $553 K | 3.42 M | Form 4 |
| filed | Ram MukundaCEO, Director | Grant or award | +2.23 M | $0.270 | $601 K | 6.88 M | Form 4 |
| filed | Claudia GrimaldiPFO, Director | Option exercise | +100,000 | — | — | 1.23 M | Form 4 |
| filed | Richard K. PrinsDirector | Option exercise | +100,000 | — | — | 1.47 M | Form 4 |
| filed | Ram MukundaCEO, Director | Option exercise | +333,333 | — | — | 4.33 M | Form 4 |
Markets and events: IGC Pharma, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 17,539 shares at $0.25
- : 12,369 shares at $0.25
- : 17,539 shares at $0.24
- : 5 shares at $0.25
- : 6,778 shares at $0.28
IGC Pharma, Inc. scorecard#
Passes 2 of the 8 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation0 of 5
Growthnot known
Profitabilitynot known
Financial health2 of 3
Shareholder returnsnot known
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
IGC Pharma, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Mar 31, 2022 | FY 2020to Mar 31, 2021 | FY 2019to Mar 31, 2020 | FY 2018to Mar 31, 2019 | FY 2017to Mar 31, 2018 | FY 2016to Mar 31, 2017 | FY 2015to Mar 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.3 | 1.3 | 0.9 | 0.4 | 0.9 | 4.1 | 5.1 | 2.2r | 0.6 | 6.4 | |
| Cost of revenue | 0.7 | 0.6 | 0.5 | 0.2 | 0.8 | 4.0 | 5.0 | 2.1r | 0.4 | 5.5 | |
| Gross profit | 0.6 | 0.7 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1r | 0.2 | — | |
| Research and development | 3.7 | 3.8 | 3.5 | 2.3 | 0.9 | 1.0 | 1.3 | 0.1 | — | — | |
| Selling, general and administrative | 4.4 | 6.8 | 8.6 | 13 | 7.9 | 6.0 | 3.5 | 1.7r | 2.3r | 2.7 | |
| Operating income | −7.4 | −9.8 | −12 | −15 | −8.7 | −6.9 | −4.6 | −1.8r | −2.1 | −2.9 | |
| Interest and finance income | — | — | — | — | — | — | — | — | 0.0 | 0.0 | |
| Interest expense and finance costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.2 | 0.2 | |
| Share of profit of associates | — | — | — | — | — | — | — | 0 | 0.3 | 0 | |
| Other non-operating income (expense) | 0.3 | 0.1 | 0.1 | 0.5 | 0.1 | 0.3 | 0.5 | 0.0r | 0.2r | 0.3 | |
| Income before tax | −7.1 | −13 | −12 | −15 | −8.8 | −7.3 | −4.1 | −1.8r | −1.8 | −2.8 | |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0r | 0.0 | 0.0 | |
| Net income including minority interests | −7.1 | −13 | −12 | −15 | −8.8 | −7.3 | −4.1 | −1.8r | −1.9 | −2.8 | |
| Minority interests' share of net income | — | — | — | — | — | — | — | 0.0r | 0.0 | −0.0 | |
| Net income attributable to shareholders | −7.1 | −13 | −12 | −15 | −8.8 | −7.3 | −4.1 | −1.8r | −1.9 | −2.8 | |
| Earnings per share, basic | -0.09 | -0.22 | — | — | -0.21 | -0.19 | -0.13 | -0.06 | -0.07 | -0.17 | |
| Earnings per share, diluted | -0.09 | -0.22 | — | — | -0.21 | -0.19 | -0.13 | -0.06 | -0.07 | -0.17 | |
| Shares, weighted average (basic) | 77 | 59 | 53 | 50 | 42 | 39 | 35 | 28 | 26 | 16 | |
| Shares, weighted average (diluted) | 77 | 59 | — | — | 42 | 39r | 0.0 | 0.0r | 26 | 16 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.4 | 1.2 | 3.2 | 10 | 15 | 7.3 | 26 | 1.7r | 0.5r | 1.5r | |
| Short-term investments | 0 | 0 | 0.2 | 0 | 0.1 | 0r | 0 | 0.1r | 1.9 | 0 | |
| Receivables | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.6r | 0.8 | 1.0r | |
| Inventory | 1.4 | 1.5 | 2.7 | 3.5 | 5.5 | 4.2 | 0.2 | 0.5r | 0 | 0.2r | |
| Other current assets | 0.3 | 0.1 | 0.3 | 0.3 | 0.2 | 0.2r | 0.0 | 0.0r | 0.2r | 0.0r | |
| Current assets | 2.9 | 3.7 | 6.5 | 15 | 24 | 18 | 27 | 3.2r | 3.6 | 3.8r | |
| Property, plant and equipment | 3.2 | 3.7 | 8.2 | 9.4 | 11 | 9.8 | 5.9 | 6.2r | 1.0 | 7.1r | |
| Right-of-use (leased) assets | 0.1 | 0.2 | 0.3 | 0.5 | 0.5 | 0.6 | 0 | — | — | — | |
| Goodwill | — | — | — | — | — | — | — | 0 | 0.2 | 1.2r | |
| Other intangible assets | 1.9 | 1.6 | 1.2 | 0.9 | 0.4 | 0.3 | 0.2 | 0.1r | 0 | 0.1r | |
| Investments in associates | — | — | — | — | — | — | — | 0.8 | 6.0 | — | |
| Long-term investments | — | — | — | 0 | 0.0 | 0.0 | — | — | — | — | |
| Non-current assets | 5.9 | 6.2 | 11 | 12 | 12 | 11 | 7.7 | 7.6r | 7.7 | 15r | |
| Total assets | 8.7 | 9.9 | 17 | 27 | 36 | 29 | 34 | 11r | 11 | 19r | |
| Accounts payable | 0.9 | 0.8 | 0.5 | 1.0 | 0.5 | 0.8 | 0.3 | 0.3r | 0.4 | 0.3r | |
| Current liabilities | 2.3 | 2.3 | 1.9 | 2.4 | 2.4 | 1.9 | 0.9 | 2.3r | 1.3 | 3.2r | |
| Long-term debt | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0 | — | — | 0.5 | 0.8r | |
| Lease liabilities (non-current) | 0.0 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0 | — | — | — | |
| Non-current liabilities | 0.2 | 0.2 | 0.4 | 0.5 | 0.7 | 0.5 | 0.0 | 0.4r | 2.6 | 1.7r | |
| Total liabilities | 2.4 | 2.6 | 2.3 | 2.9 | 3.1 | 2.4 | 0.9 | 2.8r | 3.9 | 4.9r | |
| Retained earnings | −121 | −114 | −101 | −89 | −74 | −65 | −58 | −54r | −52 | −50r | |
| Shareholders' equity | 6.3 | 7.3 | 15 | 24 | 33 | 27 | 34 | 8.1r | 7.4 | 13r | |
| Minority interests | — | — | — | — | — | — | — | 0 | −0.0 | 0.5r | |
| Total equity | — | — | — | — | 33 | 27 | 34 | 8.1r | 7.4r | 14r | |
| Total liabilities and equity | 8.7 | 9.9 | 17 | 27 | 36 | 29 | 34 | 11r | 11 | 19r | |
| Shares outstanding | 81 | 67 | 53 | 51 | 48 | 39 | 40 | 31 | 28r | 23r | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.6 | 0.6 | 0.7 | 0.7 | 0.5 | 0.1 | 0.1 | 0.0r | 0.4 | 0.7 | |
| Share-based compensation | 4.3 | 4.6 | 5.5 | 7.0 | 0.7 | 0.5 | 0.5r | 0.6 | 0.3r | 0.2 | |
| Cash from operating activities | −4.8 | −5.2 | −7.0 | −7.5 | −11 | −8.7 | −3.3 | −1.9r | −1.4 | −0.2 | |
| Capital expenditure | −0.1 | −0.1 | −0.3 | −0.2r | −1.5 | −4.4 | −0.0 | −0.1r | −0.1 | −0.1 | |
| Intangible assets bought | −0.4 | −0.4 | −0.3 | −0.5 | −0.1 | −0.1 | −0.0 | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | −0.0 | −0.1r | 0 | −0.0 | |
| Cash from investing activities | −0.4 | −0.3 | −0.2 | −0.7 | 3.4 | −9.5 | −0.3 | −0.7r | −0.2 | −0.2 | |
| Debt repaid | −0.0 | −0.0 | −0.0 | −0.0 | — | — | — | — | — | — | |
| Shares issued | 4.5 | 3.0 | 0.1 | — | 14 | −0.1 | 29 | 3.5r | 0.6 | 1.7 | |
| Cash from financing activities | 4.5 | 3.5 | 0.1 | 4.1 | 15 | −0.1 | 28 | 3.7r | 0.7 | 1.0 | |
| Exchange-rate effect on cash | — | — | — | — | 0.0 | −0.1 | −0.1 | −0.0r | −0.0 | −0.0 | |
| Change in cash | −0.8 | −2.0 | −7.3 | −4.1 | 7.3 | −18 | 24 | 1.1r | −1.0 | 0.7 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2025
What IGC Pharma, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Plant and Cannabinoid$1 M100%-5.2%
- Tolling/White labeling service$1 M91%+22%
- Infrastructure$0 M13%—
- Wellness and Lifestyle$0 M8.9%-52%
Countries and regions
- 🇺🇸 USA$1 M100%+7.6%
As of Mar 31, 2025
Where IGC Pharma, Inc. operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | $1 M100% |
| 🇮🇳 India | 4 subsidiaries | — |
| 🇨🇴 Colombia | 1 subsidiary | — |
| 🇭🇰 Hong Kong | 1 subsidiary | — |
Executive pay at IGC Pharma, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Ram Mukunda | $568 K | −$203 K | $259 K | $82000 |
| 2024Mr. Ram Mukunda | $1.8 M | $2.7 M | $717 K | — |
As of Mar 31, 2025
Events at IGC Pharma, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 11 · New debt 4 · Unregistered share sale 5 · Bylaws or fiscal year changed 2 · Shareholder vote 3
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share sale | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Acquisition or sale completed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K |
As of Jul 6, 2026
Acquisitions and funding#
3 acquisitions, $2 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Golden Gate Electronics Limited ("Golden Gate") | 2014 | — | $1 M | 51% | Annual report |
| Techni Bharathi Limited ("TBL") | 2013 | — | $0 M | — | Annual report |
| H&F Ironman Limited ("HK Ironman") | 2012 | — | $1 M | — | Annual report |
How IGC Pharma, Inc. compares in Biotechnology
- Market cap$29 M · higher than 21% of 733
- Revenue$1 M · higher than 27% of 649
- Net margin-787.2% · higher than 4% of 407
- Revenue growth-5.2% · higher than 38% of 441
- Price / sales24.9× · lower than 28% of 344
- Price / book3.9× · lower than 38% of 537
- FCF yield-16.8% · higher than 47% of 456
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| IGC Pharma, Inc.🇺🇸 | $29 M | — | -787.2% | -5.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
How current the figures are
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending March-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: methodology. Market caps in US dollars unless you switch the currency.
Work at IGC Pharma, Inc.? Verify and update this profile — free
Show IGC Pharma, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.